SCHEMBL223751

SCHEMBL223751

[CH]1NCc2[nH]c3ccccc3c21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
GPR3 P46089 2/20 0.50
HSD17B10 Q99714 2/20 0.50
KDM4E B2RXH2 5/20 0.44
HTR5A P47898 1/20 0.44
NISCH Q9Y2I1 1/20 0.44
NR2E1 Q9Y466 1/20 0.44
AHR P35869 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
KMT2A Q03164 2/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
TNKS O95271 1/20 0.41
CYP1A2 P05177 1/20 0.41
PARP1 P09874 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41
PARP15 Q460N3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1456916 0.85 HTR2A (0.51) ALDH1A1GPR3HSD17B10KDM4EHTR5A
SCHEMBL29424329 0.81 KDM4E (0.42) ALDH1A1GPR3HSD17B10KDM4EHTR5A
SCHEMBL465036 0.81 KDM4E (0.42) ALDH1A1GPR3HSD17B10KDM4EHTR5A
SCHEMBL224258 0.78 KDM4E (0.46) ALDH1A1GPR3HSD17B10KDM4EHTR5A
SCHEMBL2072294 0.73 KDM4E (0.50) ALDH1A1GPR3HSD17B10KDM4EHTR5A
Carbazole SCHEMBL30761795 0.69 ALDH1A1 (1.00) ALDH1A1GPR3HSD17B10KDM4EAHR
Carbazole SCHEMBL29355407 0.69 ALDH1A1 (1.00) ALDH1A1GPR3HSD17B10KDM4EAHR
Carbazole SCHEMBL30209164 0.69 ALDH1A1 (1.00) ALDH1A1GPR3HSD17B10KDM4EAHR
Carbazole SCHEMBL7650 0.69 ALDH1A1 (1.00) ALDH1A1GPR3HSD17B10KDM4EAHR
Carbazole SCHEMBL29627417 0.69 ALDH1A1 (1.00) ALDH1A1GPR3HSD17B10KDM4EAHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024150222-A1 IONIZABLE LIPIDS AND NANOPARTICLES COMPRISING SAME MANA BIO LTD. (IL) 2024-07-18 WO disclosed
CN-118284426-A Ophthalmic compositions and methods of use thereof 塔西亚制药公司 2024-07-02 CN disclosed
WO-2024134657-A1 PYRROLOPYRIDINE AND PYRROLOPYRIDAZINE BASED COMPOUNDS AND USE THEREOF AS PKR INHIBITORS PROTEKT THERAPEUTICS LTD. (IL) 2024-06-27 WO disclosed
CN-118146635-A Coating composition with polysiloxane modified carbon nanoparticles NGNT材料科学公司 2024-06-07 CN disclosed
EP-4376837-A1 COMPOUNDS FOR NEUTROPHIL ROS INHIBITION Immunyx Pharma Ltd. (IL) 2024-06-05 EP disclosed
US-20240156742-A1 TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2024-05-16 US disclosed
US-20240148886-A1 INTRACELLULAR DELIVERY COMPOSITIONS BIOND BIOLOGICS LTD. (IL) 2024-05-09 US disclosed
WO-2024069634-A1 MICROTUBULE TARGETING AGENTS Ariel Scientific Innovations Ltd. (IL) 2024-04-04 WO disclosed
WO-2024052923-A1 IONIZABLE LIPIDS AND COMPOSITIONS COMPRISING SAME BARCODE NANOTECH LTD. (IL) 2024-03-14 WO disclosed
EP-4326332-A1 INTRACELLULAR DELIVERY COMPOSITIONS Biond Biologics Ltd. (IL) 2024-02-28 EP disclosed
WO-2009128918-A1 COMBINATION THERAPY USING A SOLUBLE HYALURONIDASE AND A BISPHOSPHONATE HALOZYME, INC. (US) 2009-10-22 WO disclosed
US-7582794-B2 Process for the preparation of substituted 2-(phenoxymethyl)benzoic acids SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-09-01 US disclosed
WO-2009082437-A2 SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-07-02 WO disclosed
WO-2009009117-A2 CHEMOENZYMATIC PROCESSES FOR PREPARATION OF LEVETIRACETAM BIOVERDANT, INC. (US) 2009-01-15 WO disclosed
EP-1699748-B1 METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS SANOFI AVENTIS DEUTSCHLAND (DE) 2008-10-15 EP disclosed
US-20070219395-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-(PHENOXYMETHYL)BENZOIC ACIDS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-09-20 US disclosed
US-7238835-B2 Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-07-03 US disclosed
EP-1699748-A2 METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS Sanofi-Aventis Deutschland GmbH (DE) 2006-09-13 EP disclosed
US-20050171205-A1 Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-08-04 US disclosed
WO-2005061427-A2 METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219395-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-(PHENOXYMETHYL)BENZOIC ACIDS CYP2B6, CYP1B1, CYP4B1 ALDH1A1 285/4885GPR3 3846/4885HSD17B10 521/4885
US-20240156742-A1 TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS LCAT, CD47, PHOSPHO1 ALDH1A1 2268/4885GPR3 870/4885HSD17B10 1006/4885
US-20240148886-A1 INTRACELLULAR DELIVERY COMPOSITIONS ACTB, CHERP, EEA1 ALDH1A1 4745/4885GPR3 3884/4885HSD17B10 3810/4885
US-20050171205-A1 Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids CYP2B6, CYP1B1, CYP4B1 ALDH1A1 285/4885GPR3 3846/4885HSD17B10 521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.